Drug intelligence / Profile preview

xxb750

Development stage: Phase 2
Lead developer: Novartis
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

XXB750 is an investigational fully human monoclonal IgG1 antibody developed by Novartis for the treatment of resistant hypertension (rHTN) and heart failure with reduced ejection fraction (HFrEF). It acts as a selective agonist of natriuretic peptide receptor 1 (NPR1), mimicking the effects of atrial natriuretic peptide by increasing plasma cGMP, lowering blood pressure, and promoting diuresis. The drug is administered via subcutaneous injection. In clinical studies, XXB750 demonstrated safety and tolerability in patients with rHTN and HFrEF; however, development was discontinued after Phase II trials due to sponsor decision[1][3][6].

Targets

NPR1 (Natriuretic peptide receptor 1)

Beyond the preview

Go deeper on xxb750.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on xxb750.

Explore the full profile